Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622744 | 0.84 | EGFR (0.53) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4539841 | 0.84 | KDM4E (0.52) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11162210 | 0.83 | EGFR (0.61) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL20528292 | 0.83 | BACE1 (0.47) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL30503636 | 0.83 | EGFR (0.61) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL845999 | 0.76 | BACE1 (0.50) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL5262436 | 0.76 | MAP4K4 (0.46) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2002584 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL31378728 | 0.76 | PIK3CG (0.44) | ALDH1A1KDM4EMAPTBACE1EGFR | |
| SCHEMBL5048586 | 0.76 | CYP1A2 (0.57) | ALDH1A1KDM4EMAPTBACE1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025015045-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | FELICITEX THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3558321-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | NOS2, NOS1, NOS3 | ALDH1A1 375/4885KDM4E 1434/4885MAPT 4210/4885 |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | ALDH1A1 213/4885KDM4E 911/4885MAPT 4068/4885 |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | ALDH1A1 762/4885KDM4E 429/4885MAPT 2891/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | ALDH1A1 1694/4885KDM4E 2811/4885MAPT 3496/4885 |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | DYRK1A, DYRK1B, DYRK2 | ALDH1A1 3355/4885KDM4E 1573/4885MAPT 404/4885 |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | ALDH1A1 5/4885KDM4E 2179/4885MAPT 2167/4885 |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | DYRK1A, DYRK1B, DYRK2 | ALDH1A1 3355/4885KDM4E 1573/4885MAPT 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.